• FY26 revenue of $51.6M, up 27% year-over-year
• ARR as at 30 June 2026 of $38.3M
• FY26 Underlying EBITDA of $6.8M, up 34% year-over-year
• Acquisition of Kyra flow products from Telstra Health
• Strong growth in recurring revenue and long-term contracts

Alcidion Group Ltd announced its FY26 results, highlighting significant growth across all key financial metrics. The company reported a 27% increase in revenue to $51.6M, with ARR at $38.3M as of June 30, 2026. Underlying EBITDA rose 34% to $6.8M. The company experienced robust growth in recurring revenue and secured long-term contracts, including significant expansions with North Cumbria NHS and Leidos. The acquisition of Kyra flow products from Telstra Health added 33 new customers and consolidated Alcidion's position in the Australian patient flow market. The company ended FY26 with $20.6M in cash and no debt.

FY26 revenue $51.6M, ARR $38.3M, Underlying EBITDA $6.8M

Alcidion anticipates continued growth driven by strong market demand for its healthcare informatics solutions and strategic acquisitions.